Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 10/20 | 0.58 |
| ▸ | RAB9A | P51151 | 6/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.58 |
| ▸ | NPC1 | O15118 | 5/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.58 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.58 |
| ▸ | RELA | Q04206 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 6/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL268926 | 1.00 | RXFP1 (0.61) | RXFP1MAPTRAB9ASMN1; SMN2NPC1 | |
| SCHEMBL10491540 | 0.93 | MAPT (0.70) | RXFP1MAPTRAB9ASMN1; SMN2NPC1 | |
| SCHEMBL4126180 | 0.93 | MAPT (0.70) | RXFP1MAPTRAB9ASMN1; SMN2NPC1 | |
| SCHEMBL31238515 | 0.92 | MAPT (0.53) | RXFP1MAPTRAB9ASMN1; SMN2NPC1 | |
| SCHEMBL14613097 | 0.89 | L3MBTL1 (0.58) | RXFP1MAPTRAB9ASMN1; SMN2NPC1 | |
| SCHEMBL13609822 | 0.89 | NPC1 (0.55) | RXFP1MAPTRAB9ASMN1; SMN2NPC1 | |
| SCHEMBL439393 | 0.88 | RXFP1 (0.74) | RXFP1MAPTRAB9ASMN1; SMN2NPC1 | |
| SCHEMBL9551055 | 0.86 | POLB (0.54) | RXFP1MAPTRAB9ASMN1; SMN2NPC1 | |
| SCHEMBL10070045 | 0.86 | POLB (0.54) | RXFP1MAPTRAB9ASMN1; SMN2NPC1 | |
| SCHEMBL26092410 | 0.86 | POLB (0.54) | RXFP1MAPTRAB9ASMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119133264-A | Airport low reflection photovoltaic module | 山东欧圣达新能源有限公司 | 2024-12-13 | — | — | CN | claimed |
| US-9890351-B2 | Encapsulates | THE PROCTER & GAMBLE COMPANY (US) | 2018-02-13 | — | — | US | claimed |
| US-8772355-B2 | Stealth polymeric particles for delivery of bioactive or diagnostic agents | HOWARD UNIVERSITY (US) | 2014-07-08 | — | — | US | claimed |
| EP-2643372-A2 | STEALTH POLYMERIC PARTICLES FOR DELIVERY OF BIOACTIVE OR DIAGNOSTIC AGENTS | Howard University (US) | 2013-10-02 | — | — | EP | claimed |
| WO-2012071452-A2 | STEALTH POLYMERIC PARTICLES FOR DELIVERY OF BIOACTIVE OR DIAGNOSTIC AGENTS | HOWARD UNIVERSITY (US) | 2012-05-31 | — | — | WO | claimed |
| US-20120129798-A1 | STEALTH POLYMERIC PARTICLES FOR DELIVERY OF BIOACTIVE OR DIAGNOSTIC AGENTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-05-24 | — | — | US | claimed |
| US-5415864-A | Colonic-targeted oral drug-dosage forms based on crosslinked hydrogels containing azobonds and exhibiting PH-dependent swelling | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 1995-05-16 | — | — | US | claimed |
| CN-120519150-B | Up-conversion fluorescent probe, isoniazid detection method and portable isoniazid detection sensor | 中国科学院合肥物质科学研究院 | 2025-11-18 | — | — | CN | disclosed |
| CN-120519150-A | Up-conversion fluorescent probe, isoniazid detection method and portable isoniazid detection sensor | 中国科学院合肥物质科学研究院 | 2025-08-22 | — | — | CN | disclosed |
| CN-119133264-A | Airport low reflection photovoltaic module | 山东欧圣达新能源有限公司 | 2024-12-13 | — | — | CN | disclosed |
| CN-116075573-A | Sulfonated polymers | 沙特阿拉伯石油公司 | 2023-05-05 | — | — | CN | disclosed |
| CN-115551443-A | Base integrated restoration block for cutting and manufacturing method thereof | 株式会社哈斯 | 2022-12-30 | — | — | CN | disclosed |
| US-11366357-B2 | Liquid crystal display device, production method for liquid crystal display device, and retardation layer-forming monomer | SHARP KABUSHIKI KAISHA (JP) | 2022-06-21 | — | — | US | disclosed |
| US-5603953-A | HYDROPHILIC MATERIAL SURROUNDED BY MICROPOROUS SUPPORTING WALL HAVING HYDROPHOBIC LIQUID ENTRAINED IN PORES, WITH VARIABLE WATER PERMEABILITY, FOR CONTROLLED DRUG DELIVERY | PFIZER INC. (US) | 1997-02-18 | — | — | US | disclosed |
| EP-0670717-A1 | SUPPORTED LIQUID MEMBRANE DELIVERY DEVICES | PFIZER INC. (US) | 1995-09-13 | — | — | EP | disclosed |
| US-5415864-A | Colonic-targeted oral drug-dosage forms based on crosslinked hydrogels containing azobonds and exhibiting PH-dependent swelling | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 1995-05-16 | — | — | US | disclosed |
| WO-1994012159-A1 | SUPPORTED LIQUID MEMBRANE DELIVERY DEVICES | PFIZER INC. (US) | 1994-06-09 | — | — | WO | disclosed |
| EP-0544671-A4 | COLONIC-TARGETED ORAL DRUG-DOSAGE FORMS BASED ON CROSSLINKED HYDROGELS CONTAINING AZOBONDS AND EXHIBITING PH-DEPENDENT SWELLING | — | 1993-09-15 | — | — | EP | disclosed |
| EP-0544671-A1 | COLONIC-TARGETED ORAL DRUG-DOSAGE FORMS BASED ON CROSSLINKED HYDROGELS CONTAINING AZOBONDS AND EXHIBITING pH-DEPENDENT SWELLING | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 1993-06-09 | — | — | EP | disclosed |
| WO-1991016057-A1 | COLONIC-TARGETED ORAL DRUG-DOSAGE FORMS BASED ON CROSSLINKED HYDROGELS CONTAINING AZOBONDS AND EXHIBITING pH-DEPENDENT SWELLING | UNIVERSITY OF UTAH (US) | 1991-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129798-A1 | STEALTH POLYMERIC PARTICLES FOR DELIVERY OF BIOACTIVE OR DIAGNOSTIC AGENTS | SSTR5, SSTR3, SSTR1 | RXFP1 1090/4885MAPT 2486/4885RAB9A 3487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.